tbuckley/cabot-search huggingface dataset:
Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation
Authors: Shinji Itoh, Tomoharu Yoshizumi, Kyohei Yugawa, Daisuke Imai, Shohei Yoshiya, Kazuki Takeishi, Takeo Toshima, Noboru Harada, Toru Ikegami, Yuji Soejima, Kenichi Kohashi, Yoshinao Oda, Masaki Mori
Journal: Hepatology (2020)

Background and Aims We investigated the prognostic value of programmed death ligand 1 (PD‐L1) expression, tumor‐infiltrating CD8‐positive T‐cell status, and their combination in hepatocellular carcinoma (HCC). Their association with PD‐L1 expression and vascular formation was further explored. Approach and Results Using a database of 387 patients who underwent hepatic resection for HCC, immunohistochemical staining of PD‐L1, CD8, and CD34 was performed. Additionally, we undertook an enzyme‐linked immunosorbent assay for soluble PD‐L1. Compared with patients with HCC and PD‐L1–negative expression (n = 311), patients with HCC and PD‐L1–positive expression (n = 76) showed significantly worse overall survival (OS; multivariate hazard ratio, 2.502; 95% confidence interval [CI], 1.716‐3.649; P &lt; 0.0001). The presence of tumor‐infiltrating CD8‐positive T cells was significantly correlated with longer OS (multivariate hazard ratio, 0.383; 95% CI, 0.274‐0.537; P &lt; 0.0001). Stratification based on PD‐L1 expression in cancer cells and tumor‐infiltrating CD8‐positive T‐cell status was also significantly associated with OS (log‐rank, P &lt; 0.0001). HCC with PD‐L1–positive expression was significantly correlated with positivity for vessels that encapsulated tumor clusters. Serum PD‐L1 levels were significantly higher in the group of patients who had PD‐L1–positive expression than in the group of patients who had PD‐L1–negative expression ( P = 0.0158). Conclusions PD‐L1 expression in cancer cells was associated with a poor clinical outcome and vascular formation in patients with HCC. Additionally, the combination of PD‐L1 expression with tumor‐infiltrating CD8‐positive T‐cell status enabled further classification of patients based on their clinical outcome. Thus, PD‐L1 expression in cancer cells and tumor‐infiltrating CD8‐positive T‐cell status might serve as predictive tissue biomarkers.
Association of robotic partial nephrectomy for clinical T2a renal mass with improved trifecta outcome compared to open partial nephrectomy: A single surgeon comparative analysis.
Authors: Fady Ghali, Amr A. Elbakry, Zachary Hamilton, Ryan Nasseri, Ahmed Eldefrawy, Stephen T. Ryan, Kendrick Yim, Sunil Patel, Aaron Bradshaw, Margaret Meagher, Madhumitha Reddy, Hak J. Lee, Ithaar Derweesh
Journal: Journal of Clinical Oncology (2020)

653 Background: We compared surgical quality and functional outcomes of robotic partial nephrectomy (RPN) and open PN (OPN) for cT2a renal masses (cT2aRM). Methods: Retrospective analysis of 150 consecutive patients [RPN 59/OPN 91] from 6/2008 to 6/2016. Main outcome was achievement of Trifecta [negative surgical margin, no major urologic complications, and ≥90% preservation of estimated glomerular filtration rate (eGFR)]. Multivariable analysis was performed to identify factors of Trifecta attainment. Results: Mean tumor size (RPN 7.9 vs. OPN 8.4 cm, p=0.139) and median RENAL score (p=0.361) were similar. No difference was noted for positive margins (RPN 3.4% vs. OPN 1.1%, p=0.561), DeGFR (RPN -6.2 vs. OPN -7.8, p=0.543), and ≥90% eGFR recovery (RPN 54.1% vs. OPN 47.2%, p=0.504). RPN had lower blood loss (p=0.015), hospital stay (p=0.013), and Clavien ≥3 complications (RPN 5.1% vs. OPN 16.5%, p=0.041). Trifecta rate was significantly higher in RPN (47.5% vs. 34.0%, p=0.041). Multivariable analysis demonstrated decreasing RENAL score (OR 1.11, p&lt;0.001), RPN (OR 1.2, p=0.013), and decreasing EBL (OR 1.02, p=0.016) to be associated with Trifecta attainment. Conclusions: RPN provided similar functional and oncologic precision to OPN, while being associated with improvements in major complications, the latter of which was reflected in a higher rate of Trifecta achievement for RPN. RPN may be considered to be a first-line option for select patients with cT2aRM when feasible and safe.
Epidemiology and regional variation in the mortality of patients admitted with prostate cancer in the United States.
Authors: Arya Mariam Roy, Manojna Konda, Akshay Goel, Rashmi Verma
Journal: Journal of Clinical Oncology (2020)

69 Background: Prostate cancer is one of the most common cancers in men and one of the leading causes of death among men of all races worldwide. Prostate cancer prevalence and mortality vary substantially by race, ethnicity and geography. The reason behind the disparity is unclear, however, access to screening and treatment, variation in exposure to risk factors, genetic susceptibility, lifestyle practices are the suggested factors that affect the disparity. Methods: We conducted a retrospective analysis of the National Inpatient Sample Database for the year 2016. Patients who were admitted with a principal diagnosis of Malignant Neoplasm of Prostate (MNP) were identified using ICD-10 codes. The epidemiology, racial disparities and regional variations in the mortality of prostate cancer, trend in the cost and length of stay were studied. Results: A total of 39,853 hospitalizations were identified with a principal diagnosis of MNP. The prevalence of MNP was found to be 0.56% with mean age of diagnosis 71.36 ± 0.55. The prevalence of prostate cancer was found to be highest in African Americans (0.65%), followed by Caucasians (0.60%). The disease-specific mortality rate for MNP was 3.45% (n=1,375). African Americans (AA) had 32% more risk of dying with prostate cancer when compared to all the other groups (OR= 1.322, P= 0.001, 95% CI= 1.14-1.52). Caucasians had 25% less chance of dying and Hispanic had 28% less chance of dying with prostate cancer when compared to AA (OR= 0.755, P= 0.001, CI= 0.65-0.87 vs OR= 0.72, P= 0.016, CI= 0.56- 0.94). Those who admitted to West were 22% more likely to die and those admitted to Northeast were 18% more likely to die when compared to Midwest and south regions (OR= 1.22, P= 0.037, CI= 1.01- 1.47 vs OR= 1.18, P= 0.062, CI= 0.91-1.4). The length of stay and also cost of stay were found to be highest for African American population. Conclusions: The prevalence, mortality of prostate cancer, cost and length of inpatient stay were highest among African Americans. There was a statistically significant difference in the mortality rate of prostate cancer based on the hospital regions in the United States. More studies are needed to better understand the reasons behind the regional difference.
Cognitive Remediation Therapy Does Not Enhance Treatment Effect in Obsessive-Compulsive Disorder and Anorexia Nervosa: A Randomized Controlled Trial
Authors: Boris van Passel, Unna N. Danner, Alexandra E. Dingemans, Emmeke Aarts, Lot C. Sternheim, Eni S. Becker, Annemarie A. van Elburg, Eric F. van Furth, Gert-Jan Hendriks, Daniëlle C. Cath
Journal: Psychotherapy and Psychosomatics (2020)

&lt;b&gt;&lt;i&gt;Background:&lt;/i&gt;&lt;/b&gt; Guideline-recommended therapies are moderately successful in the treatment of obsessive-compulsive disorder (OCD) and anorexia nervosa (AN), leaving room for improvement. Cognitive inflexibility, a common trait in both disorders, is likely to prevent patients from engaging in treatment and from fully benefiting from existing therapies. Cognitive remediation therapy (CRT) is a practical augmentation intervention aimed at ameliorating this impairing cognitive style prior to disorder-specific therapy. &lt;b&gt;&lt;i&gt;Objective:&lt;/i&gt;&lt;/b&gt; To compare the effectiveness of CRT and a control treatment that was not aimed at enhancing flexibility, named specialized attention therapy (SAT), as add-ons to treatment as usual (TAU). &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; In a randomized controlled multicenter clinical trial, 71 adult patients with OCD and 61 with AN were randomized to ten twice-weekly sessions with either CRT or SAT, followed by TAU. Patients were evaluated at baseline, post-CRT/SAT, and after 6 and 12 months, with outcomes being quantified using the Yale-Brown Obsessive Compulsive Scale for OCD and the Eating Disorder Examination Questionnaire for AN. &lt;b&gt;&lt;i&gt;Results:&lt;/i&gt;&lt;/b&gt; Across study groups, most importantly CRT+TAU was not superior to control treatment (SAT)+TAU in reducing OCD and AN pathology. Contrary to expectations, SAT+TAU may have been more effective than CRT+TAU in patients being treated for OCD. &lt;b&gt;&lt;i&gt;Conclusions:&lt;/i&gt;&lt;/b&gt; CRT did not enhance the effect of TAU for OCD and AN more than SAT. Unexpectedly, SAT, the control condition, may have had an augmentation effect on TAU in OCD patients. Although this latter finding may have been due to chance, the effect of SAT delivered as a pretreatment add-on intervention for adults with OCD and AN merits future efforts at replication.
Evaluation of co-morbid conditions among refractory or unexplained chronic cough patients in two phase 2 randomized controlled trials
Authors: Mandel Sher, Surinder Birring, Alyn Morice, Lorcan McGarvey, Jacky Smith, Wen-chi Wu, Jonathan Schelfhout, David Muccino
Journal: Journal of Allergy and Clinical Immunology (2020)
Transfection with Cadherin-related Family Member 3 Variant Increases Eosinophil Adhesion to Transfected Cells and Superoxide Anion Generation
Authors: Kazuyuki Nakagome, Toshiaki Shimizu, Yury Bochkov, Toru Noguchi, Takehito Kobayashi, Tomoyuki Soma, James Gern, Makoto Nagata
Journal: Journal of Allergy and Clinical Immunology (2020)
Abstract 15717: PDGFRalpha Drives Pulmonary Vascular Progenitor Cells Recruitment, Vascular Remodeling and Pulmonary Hypertension Development
Authors: Julien Solinc, Jessica Raimbault-Machado, Lamiaa El Bernoussi, Bénédicte Hoareau-Coudert, Virginie Monceau, Fabrice Atassi, Giovanna Marazzi, David A Sassoon, Richard Harvey, Daniel Christ, Peter Schofield, Catherine Pavoine, Florent Soubrier, Sophie Nadaud
Journal: Circulation (2019)

Introduction: Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and neomuscularization. We identified pulmonary vascular progenitor cells, characterized by PW1, CD34 and...
Recent advances in periodontal regeneration: A biomaterial perspective
Authors: Yongxi Liang, Xianghong Luan, Xiaohua Liu
Journal: Bioactive Materials (2020)

Periodontal disease (PD) is one of the most common inflammatory oral diseases, affecting approximately 47% of adults aged 30 years or older in the United States. If not treated properly, PD leads to degradation of periodontal tissues, causing tooth movement, and eventually tooth loss. Conventional clinical therapy for PD aims at eliminating infectious sources, and reducing inflammation to arrest disease progression, which cannot achieve the regeneration of lost periodontal tissues. Over the past two decades, various regenerative periodontal therapies, such as guided tissue regeneration (GTR), enamel matrix derivative, bone grafts, growth factor delivery, and the combination of cells and growth factors with matrix-based scaffolds have been developed to target the restoration of lost tooth-supporting tissues, including periodontal ligament, alveolar bone, and cementum. This review discusses recent progresses of periodontal regeneration using tissue-engineering and regenerative medicine approaches. Specifically, we focus on the advances of biomaterials and controlled drug delivery for periodontal regeneration in recent years. Special attention is given to the development of advanced bio-inspired scaffolding biomaterials and temporospatial control of multi-drug delivery for the regeneration of cementum-periodontal ligament-alveolar bone complex. Challenges and future perspectives are presented to provide inspiration for the design and development of innovative biomaterials and delivery system for new regenerative periodontal therapy.
PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma
Authors: Masaharu Kawashima, Joaquim Carreras, Hiroshi Higuchi, Ryutaro Kotaki, Takahiro Hoshina, Kazuki Okuyama, Naoto Suzuki, Masatoshi Kakizaki, Yuji Miyatake, Kiyoshi Ando, Masafumi Nakayama, Shinjiro Umezu, Ryouichi Horie, Yuriko Higuchi, Koko Katagiri, Susumu Goyama, Toshio Kitamura, Kenji Chamoto, Shingo Yano, Naoya Nakamura, Ai Kotani
Journal: Leukemia (2020)
Revision of CHAARTED and LATTITUDE criteria among Japanese de novo metastatic prostate cancer patients.
Authors: Shinichi Sakamoto, Yasutaka Yamada, Junryo Rii, Satoshi Yamamoto, Shuhei Kamada, Yusuke Imamura, Kazuyoshi Nakamura, Akira Komiya, Hiroomi Nakatsu, Tomohiko Ichikawa
Journal: Journal of Clinical Oncology (2020)

132 Background: Based on the high response rate to the standard androgen deprivation therapy (ADT), the Japanese cohort in LATTITUDE study failed to show the survival benefit by early Abiraterone. In order to identify the "true high-risk" patients, we studied the prognostic factors among Japanese de novo metastatic prostate cancer patients who fit CHAARTED and LATITUDE criteria. Methods: We retrospectively studied patients who fit CHAARTED (292 patients) and LATITUDE (294 patients) criteria from Japanese multi-institutions. All patients received ADT with bicalutamide as an initial treatment. Factors related to overall survival (OS) and progression-free survival (PFS) were statistically analyzed. Results: The median OS was 56 mo and 57 mo in patients who met the CHAARTED and the LATITUDE criteria, respectively. In patients who met CHAARTED criteria, LDH (HR2.6, p &lt; 0.00001) and CRP (HR1.7, p = 0.042) were independent risk factors for OS. In patients who met LATTITUDE criteria, GS≥9 (HR1.7, p = 0.0378) and LDH (HR2.9, p &lt; 0.0001) were independent risk factors for OS. Modified CHAARTED criteria by adding LDH and CRP showed a significant difference in OS (HR2.8, p &lt; 0.0001) with a comparative median OS (30 mo) to placebo of CHAARTED trial (32 mo). Modified LATTITUDE criteria by adding GS≥9 and LDH, showed a significant difference in OS (HR2.7, p &lt; 0.0001) with a comparative median OS (33 mo) to placebo of LATTITUDE trial (34 mo). Conclusions: Modified criteria may potentially elucidate the true "high-volume" and "high-risk" patients in the Japanese cohort who require early intensive therapy.[Table: see text]
Antigen analysis of shrimp allergy using clinical research system for allergic disease “MINERVA”
Authors: Masashi Nakamura, Akiko Yagami, None nayu sato, Satoshi Ohno, tomomi sakai, Yuji Aoki, None kayoko suzuki, Naoshi Shimojo, hiroki kitano, Kayoko Matsunaga
Journal: Journal of Allergy and Clinical Immunology (2020)
Abstract 15638: Impact of Cilostazol Treatment on Prevention of Femoropopliteal In-Stent Restenosis: A Meta-Analysis
Authors: Jae-Sik Jang, Young-Ah Park, Han-Young Jin, Jeong-Sook Seo, Tae-Hyun Yang, Dae-Kyeong Kim, Dong-Soo Kim, Yong-Rak Cho
Journal: Circulation (2018)

Introduction: Cilostazol has reduced restenosis and repeat revascularization in patients undergoing femoropopliteal stent implantation. The objective of this study was to evaluate the impact of cil...
The Alzheimer’s Disease Amyloid-Beta Hypothesis in Cardiovascular Aging and Disease
Authors: Dimitrios A. Stakos, Kimon Stamatelopoulos, Dimitrios Bampatsias, Marco Sachse, Eleftherios Zormpas, Nikolaos I. Vlachogiannis, Simon Tual-Chalot, Konstantinos Stellos
Journal: Journal of the American College of Cardiology (2020)

Aging-related cellular and molecular processes including low-grade inflammation are major players in the pathogenesis of cardiovascular disease (CVD) and Alzheimer's disease (AD). Epidemiological studies report an independent interaction between the development of dementia and the incidence of CVD in several populations, suggesting the presence of overlapping molecular mechanisms. Accumulating experimental and clinical evidence suggests that amyloid-beta (Aβ) peptides may function as a link among aging, CVD, and AD. Aging-related vascular and cardiac deposition of Αβ induces tissue inflammation and organ dysfunction, both important components of the Alzheimer's disease amyloid hypothesis. In this review, the authors describe the determinants of Aβ metabolism, summarize the effects of Aβ on atherothrombosis and cardiac dysfunction, discuss the clinical value of Αβ1-40 in CVD prognosis and patient risk stratification, and present the therapeutic interventions that may alter Aβ metabolism in humans.
Examination of Aeroallergen-Specific Immunoglobulin G4 (sIgG4) in Patients with Eosinophilic Esophagitis (EoE)
Authors: Rung-chi Li, Jeffrey Wilson, Lisa Workman, Barrett Barnes, Bryan Sauer, Thomas Platts-Mills, Emily McGowan
Journal: Journal of Allergy and Clinical Immunology (2020)
Differential Transcriptomic Response To Aspirin Challenge In Blood Eosinophils From Patients With Aspirin Exacerbated Respiratory Disease (AERD)
Authors: Elina Jerschow, Anand Kumar Andiappan, Zhen Ren, Jidong Shan, Bernett Lee, Mohammad Asad, Simon Spivack, David Rosenstreich, Olaf Rotzschke, Steven Porcelli
Journal: Journal of Allergy and Clinical Immunology (2020)
Framework for establishing integrated kidney care programs in low- and middle-income countries
Authors: Marcello Tonelli, Victoria Nkunu, Cherian Varghese, Ali K. Abu-Alfa, Mona N. Alrukhaimi, Bassam Bernieh, Louise Fox, John Gill, David C.H. Harris, Fan Fan Hou, Philip J. O’Connell, Harun Ur Rashid, Abdou Niang, Shahrzad Ossareh, Vladimir Tesar, Elena Zakharova, Chih-Wei Yang
Journal: Kidney International Supplements (2020)
Endoscopic ultrasound-guided hepatogastrostomy to treat a biliocutaneous fistula
Authors: Didem Saka, Erol Barbur, Can Boynukara, Betul Piyade, Gurhan Sisman
Journal: Endoscopy (2020)

We present the case of a 39-year-old woman with a biliocutaneous fistula and a history of surgery for colon cancer. Metastasis to the left lobe of the liver had been detected 3 months before her referral to us and she had been treated with endoscopic retrograde cholangiopancreatography (ERCP)-guided insertion of an uncovered self-expandable metal stent (SEMS; 8-cm long) for obstructive jaundice caused by the metastasis. Post-procedural swelling appeared in the upper abdominal region and subsequently a fistula developed with bilious discharge from the skin over the right upper quadrant, which persisted for 3 months.
Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors
Authors: S.J. Isakoff, J. Tabernero, L.R. Molife, J.-C. Soria, A. Cervantes, N.J. Vogelzang, M.R. Patel, M. Hussain, A. Baron, G. Argilés, P.R. Conkling, D. Sampath, D. Maslyar, P. Patel, W. Chan, S. Gendreau, L. Musib, N. Xu, H. Ma, K. Lin, J. Bendell
Journal: Annals of Oncology (2020)

This phase Ib study evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of the oral AKT inhibitor ipatasertib and chemotherapy or hormonal therapy in patients with advanced or metastatic solid tumors to determine combined dose-limiting toxicities (DLTs), maximum tolerated dose, and recommended phase II doses and schedules.The clinical study comprised four combination treatment arms: arm A (with docetaxel), arm B [with mFOLFOX6 (modified leucovorin, 5-fluorouracil, and oxaliplatin)], arm C (with paclitaxel), and arm D (with enzalutamide). Primary endpoints were safety and tolerability; secondary endpoints were pharmacokinetics, clinical activity per Response Evaluation Criteria in Solid Tumors v1.1, and prostate-specific antigen levels.In total, 122 patients were enrolled. Common adverse events were diarrhea, nausea, vomiting, decreased appetite, and fatigue. The safety profiles of the combination regimens were consistent with those of the background regimens, except for diarrhea, hyperglycemia, and rash, which were previously observed with ipatasertib treatment. The only combination DLT across all treatment arms was one event of grade 3 dehydration (ipatasertib 600 mg and paclitaxel). Recommended phase II doses for ipatasertib were 600 mg (and mFOLFOX6) and 400 mg (and paclitaxel), respectively. The maximum assessed dose of ipatasertib 600 mg combined with docetaxel or enzalutamide was well tolerated. Coadministration with enzalutamide (a cytochrome P450 3A inducer) resulted in approximately 50% lower ipatasertib exposure.Ipatasertib in combination with chemotherapy or hormonal therapy was well tolerated with a safety profile consistent with that of ATP-competitive AKT inhibitors.NCT01362374.
5-Grass-Pollen SLIT Effectiveness In Seasonal Allergic Rhinitis: Impact Of Sensitization To Subtropical Grass Pollen
Authors: Sheryl Van Nunen, Melanie Burk, Pamela Burton, Geoffrey Ford, Richard Harvey, Ian Humphrey, Alexander Lozynsky, Elizabeth Pickford, Joanne Smart, Michael Sutherland, Frank Thien, Heinrich Weber, Harry Zehnwirth, Constance Katelaris
Journal: Journal of Allergy and Clinical Immunology (2020)
TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity
Authors: Qiaoshi Lian, Shanshan Yan, Qi Yin, Chenghua Yan, Wanwei Zheng, Wangpeng Gu, Xinhao Zhao, Weiguo Fan, Xuezhen Li, Liyan Ma, Zhiyang Ling, Yaguang Zhang, Jie Liu, Jinsong Li, Bing Sun
Journal: Cellular and Molecular Immunology (2020)
The ASTHMAXcel Adventures Mobile Application for Pediatric Patients: A Subgroup Analysis Singh A, Hsia B, Njeze O, Cosar E, Lin I, Jariwala SP. Division of Allergy/Immunology, Albert Einstein College of Medicine, Bronx, NY.
Authors: Anjani Singh, Brian Hsia, Obumneme Njeze, Emine Cosar, Iris Lin, Sunit Jariwala
Journal: Journal of Allergy and Clinical Immunology (2020)
Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer.
Authors: Peter Eoin Lonergan, Samuel L. Washington, Shoujun Zhao, Janet E. Cowan, Hao Nguyen, Katsuto Shinohara, Matthew R. Cooperberg, Peter Carroll
Journal: Journal of Clinical Oncology (2020)

290 Background: Active surveillance (AS) is recognized as the preferred treatment for low risk prostate cancer (PCa). No validated clinical tools currently exist to standardize the frequency of biopsies. We aimed to determine predictors of biopsy upgrading in a contemporary cohort of patients on AS. Methods: Men enrolled on AS at UCSF between 2000-2016 were included. The genomic tests used were Oncotype DX, Decipher and Prolaris. Biopsy upgrade was defined as ISUP grade group ≥ 2 on subsequent biopsy. PSA kinetics was calculated using a linear mixed-effects model for log of PSA, adjusted for clinical characteristics. Multivariable Cox proportional hazards regression models were utilized to identify factors associated with risk of upgrade on follow-up at first surveillance biopsy and at 3, 5 and 10 years. Results: 1,303 men were included. Upgrade-free survival at 3, 5 and 10 years was 73%, 53% and 27% respectively. Median time between diagnostic biopsy and first surveillance biopsy was 13 months (IQR 9-16) with the risk of upgrade at first surveillance biopsy associated with PSA density (hazard ratio [HR] 2.761, 95% confidence interval [CI] 1.895-4.023), and “high” risk genomic score (HR 1.867, 95% CI 1.025-3.401) on multivariable analysis after adjustments. Independent variables significantly associated with risk of upgrade at first surveillance biopsy and at 3, 5 and 10 years on multivariable analysis after adjustments are shown. Conclusions: Our findings suggest that genomic scores and PSA density are risk factors for biopsy upgrading within 3 years of starting AS, however PSA kinetics is associated with risk of upgrade at 5 and 10 years. When used in tandem, genomic scores may identify a subset eligible for AS who could potentially adopt a less intensive surveillance regimen.[Table: see text]
Conjugation of haloperidol to PEG allows peripheral localisation of haloperidol and eliminates CNS extrapyramidal effects
Authors: Az Alddien Natfji, Dmitry O. Nikitin, Irina I. Semina, Rouslan I. Moustafine, Vitaliy V. Khutoryanskiy, Hong Lin, Gary J. Stephens, Kimberly A. Watson, Helen M.I. Osborn, Francesca Greco
Journal: Journal of Controlled Release (2020)